STAT3 controls IL6-dependent regulation of serotonin transporter function and depression-like behavior

Eryan Kong1, Sonja Sucic2, Francisco J. Monje1, Sonali N. Reisinger1, Giorgia Savalli1, Weifei Diao1, Deeba Khan1, Marianne Ronovsky1, Maureen Cabatic1, Florian Koban1, Michael Freissmuth2 & Daniela D. Pollak1

1Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, 2Department of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna.

Experimental evidence suggests a role for the immune system in the pathophysiology of depression. A specific involvement of the proinflammatory cytokine interleukin 6 (IL6) in both, patients suffering from the disease and pertinent animal models, has been proposed. However, it is not clear how IL6 impinges on neurotransmission and thus contributes to depression. Here we tested the hypothesis that IL6-induced modulation of serotonergic neurotransmission through the STAT3 signaling pathway contributes to the role of IL6 in depression. Addition of IL6 to JAR cells, endogenously expressing SERT, reduced SERT activity and downregulated SERT mRNA and protein levels. Similarly, SERT expression was reduced upon IL6 treatment in the mouse hippocampus. Conversely, hippocampal tissue of IL6-KO mice contained elevated levels of SERT and IL6-KO mice displayed a reduction in depression-like behavior and blunted response to acute antidepressant treatment. STAT3 IL6-dependently associated with the SERT promoter and inhibition of STAT3 blocked the effect of IL6 in-vitro and modulated depression-like behavior in-vivo.

These observations demonstrate that IL6 directly controls SERT levels and consequently serotonin reuptake and identify STAT3-dependent regulation of SERT as conceivable neurobiological substrate for the involvement of IL6 in depression.
The herein reported reduction in despair-related immobility in the FST in IL6-KO is in agreement with previous reports. The observed significant increase in sucrose preference in IL6-KO mice, which is indicative of less susceptibility to depression-related anhedonia, confirms an earlier description of enhanced sucrose consumption of IL6-KO mice. This potential resilience of IL6-KO mice is also in line with the described resistance of IL6-KO mice to the induction of a depression-like phenotype, verified in two independent animal models. While a direct causal relationship between elevated levels of SERT and the altered depression-related phenotype in IL6-KO mice cannot be established in the present study, our observations of augmented SERT expression in IL6-KO mice strikingly mirror image the reported depression-like behavior characteristics of SERT-deficient mice (SERT-KO). These results suggest that - contrary to what is expected given the dampening effects of SSRIs on SERT activity and their role as pharmacological antidepressants - depression-like behavior could be associated with decreased SERT levels. This hypothesis is further supported by findings of reduced SERT expression in two independent stress-based animal models of depression.

To unveil the regulatory principle mediating the effects of IL6 on SERT levels and depression-like behavior, the relevance of the STAT3 signaling cascade - the predominant mechanism by which transcriptional control upon IL6-receptor activation is exerted - was investigated in vitro and in vivo. Incubation of JAR cells with IL6 resulted in increased levels of active, phosphorylated STAT3.

Figure 1 | SERT expression is modulated by IL6 in vitro and in vivo. (a) JAR cells (5 x 10⁵ cells) were incubated for 48 h either in the absence (control) or presence of IL6 (50 ng/ml). The activity of SERT was quantified by measuring specific cellular uptake of 0.1 μM [³H]5-HT (p = 0.0001; t₁₁₁ = 6.308; n = 9 per group). (b) Kinetic characterization of [³H]5-HT uptake in JAR cells: Kᵡ values were 7.39 ± 2.24 μM (control) and 3.70 ± 1.46 μM (IL6); the Vₘₐₓ values were 23.2 ± 7.9 (control) and 11.9 ± 4.1 pmol/10⁶ cells/min (IL6). (c) SERT mRNA (qRT-PCR) (p = 0.0024; t₁₁₁ = 5.676; n = 5–6 per group) and (d) protein levels (Western Blot) (p = 0.0362; t₁₂₇ = 3.622; n = 4 per group) in untreated control and IL6 treated JAR cells. The blot is a representative of four independent experiments and blot images were cropped for comparison. (e) SERT mRNA levels in untreated (control) and IL6 injected (i.c.v.) mice (p = 0.0418; t₁₇₉ = 5.272; n = 4 to 6 per group). Data are depicted as mean ±/SEM. *p < 0.05, **p < 0.01.
(Figure 3a and 3b) and blockage of the IL6 receptor with the monoclonal antibody tocilizumab and of STAT3 by stattic (a small-molecule inhibitor of STAT3 activation and dimerization16), blunted the effect of IL6 on [3H]5-HT uptake (Figure 3c). Assuming that the increase of phosphorylated STAT3 was directly relevant to the regulation of SERT expression, STAT3 ought to reside on the SERT promoter. This prediction was tested using chromatin immunoprecipitation (ChIP) which revealed binding of STAT3 to the SERT

Figure 2 | SERT expression and depression-like behavior in IL6-KO mice. (a) SERT raphe nuclei mRNA levels (qRT-PCR) (p = 0.0032; t(7) = 3.984; n = 4 per group), (b) SERT hippocampal protein (p = 0.0231; t(7) = 3.236; n = 4 per group), (c) radioligand binding assays with the selective SERT ligand [3H]citalopram (2 nm) on synaptosomal membranes prepared from cortical tissue (p = 0.010; t(7) = 2.885; n = 8–10 per group) and (d) DAT striatal protein levels (p = 0.1428; t(7) = 1.737; n = 4 group) in wild type (WT) and IL6-KO mice. The blots are each representative of four independent experiments and blot images were cropped for comparison (e) Percentage of time spent immobile and response to acute injection of Escitalopram (and saline control) in the Forced Swim Test (main effect of strain $F_{(2,17)} = 4.99$, p = 0.0423, main effect of treatment $F_{(2,17)} = 4.52$, p = 0.0523, strain x treatment interaction $F_{(2,17)} = 9.41$, p = 0.0083; n = 4 to 5 per group), (f) relative sucrose preference in the Sucrose Preference Test (p = 0.0461, t(17) = 2.151, n = 9 to 10 per group) and (g) latency to feed in the Novelty Suppressed Feeding test (p = 0.0134, t(17) = 2.76, n = 9 to 10 per group). Data are depicted as mean ± SEM. N.S. not significant, * p < 0.05, ** p < 0.01.
Figure 3 | STAT3 controls SERT expression and function and modulates depression-like behavior. Time course of phospho-STAT3 and total STAT3 protein levels (Western Blot) in untreated control (−) and IL6 treated (IL6) JAR cells: (a) Western Blot image representative of three independent experiments with blot images cropped for comparison and (b) result of quantification (main effect of time $F_{(2,23)} = 226.98$, $p = 0.0001$, main effect of treatment $F_{(2,23)} = 1796.69$, $p = 0.0001$, time x treatment interaction $F_{(2,23)} = 62.55$, $p = 0.0001$; $n = 3$ per group). (c) Specific cellular $[3H]5$-HT uptake of JAR cells after 48 h of incubation with IL6, IgG1, tocilizumab (Toci), Stattic or combinations thereof and in untreated controls respectively. Relative specific $[3H]5$HT uptake values were quantified by the ratio of individual specific uptake values against that of control ($p = 0.008$, $F_{(6,22)} = 7.17$; $n = 3–4$ per group). (d) Chromatin immunoprecipitation (ChIP) analysis of STAT3 binding to the SERT promoter in untreated (control) and IL6 treated JAR cells ($p = 0.0001, t_{(9)} = 6.767, n = 6$ per group). Time course of SERT hippocampal protein levels (Western Blot) of vehicle control and Stattic treated mice: (e) Western Blot image representative of three independent experiments with blot images cropped for comparison and (f) result of quantification (main effect of time $F_{(1,29)} = 242.41$, $p = 0.0001$, main effect of treatment $F_{(4,29)} = 1496.39$, $p = 0.0001$, time x treatment interaction $F_{(4,29)} = 416.50$, $p = 0.0001$; $n = 3$ per group). (g) Percentage of time spent immobile in the Forced Swim Test in vehicle control and Stattic treated mice 24 hrs after i.p. injection ($p = 0.0028, t_{(7)} = 4.487$, $n = 4$ to 5 per group). Data are depicted as mean $\pm /-\$ SEM. N.S. not significant, * $p < 0.05$, ** $p < 0.01$; results of post-hoc pairwise comparisons are indicated in (c).
promoter under basal conditions together with a substantial enhancement in IL6 treated JAR cells (Figure 3d). Finally, we set-out to examine the direct involvement of STAT3 in depression-like behavior and found that – as expected – pharmacological inhibition of STAT3 elevated SERT expression and reduced depression-like behavior in wild-type mice (Figure 3e–g).

In the present study behavioral performance and gene expression were evaluated in different cohorts of animals, since prior testing, specifically using behavioral tests associated with acute stress exposure (such as the FST), could bias subsequent molecular analyses, as shown for several proteins, including SERT\(^\text{17}\). Hence this design does not allow investigating a potential correlation between immobility in the FST and hippocampal SERT expression. Interestingly however, a recent study investigating behavioral despair in the FST and hippocampal SERT expression in different mouse strains did not reveal a correlation between SERT expression and immobility in the FST, neither at baseline nor after Fluoxetine treatment\(^\text{18}\).

In summary, results of the present study firstly demonstrate the direct regulatory constraint of IL6-induced STAT3 signaling on SERT expression, function and depression-like behavior in the mouse (Figure 4).

While previous experiments have documented that other cytokines, such as IL-1\(\beta\) and tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), can modulate SERT activity in the mouse brain\(^\text{9}\), these effects occur at the posttranslational level\(^\text{8,9,19}\). Our data collectively propose a novel concept in which the immune system, through activation of a canonical signaling pathway, exerts control over the expression of a neurotransmitter transporter hereby participating in the modulation of the behavioral output of the brain.

**Methods**

**Materials.** [\(\text{[H]}\) 5-HT (28.1 Ci/mmol) and \(\text{[H]}\) Citalopram (85.6 Ci/mmol) were purchased from Perkin Elmer (Boston, MA, USA). Cell culture media, supplements and antibiotics were all purchased from Invitrogen Corporation (Carlsbad, CA, USA). Human and mouse recombinant IL6 were obtained from eBioscience (San Diego, CA, USA). Stattic and Escitalopram were supplied by Sigma (Sigma Aldrich, Vienna, Austria). Tocilizumab was obtained from Roche (Vienna, Austria). Primary antibodies used were anti-STAT3 (Cell Signaling, #9139, Boston, MA, USA), anti-phospho-STAT3 (Cell Signaling, #9145), anti-beta-Tubulin (AbFrontier, #L1F-

![Figure 4](https://www.nature.com/scientificreports)
described in IL6 treated (50 ng/ml, 48 h) and untreated control JAR cells. After analysis were carried out as previously described19. Relative mRNA expression of SCIENTIFIC

144TM, Manassas, VA, USA) were cultured in RPMI 1640 medium, supplemented (DMEM), supplemented with 10% fetal calf serum, 1% penicillin/streptomycin and

Chromatin immunoprecipitation assay (ChIP)

Real time polymerase chain reaction (qRT-PCR)

(Bundesministerium für Wissenschaft und Forschung) and carried out according to

study were approved by the national ethical committee on animal care and use

absence or presence of 10 M NaCl. 3% Na4P7O2, 10 mm EDTA, 10 mm NaF, 1 mM Na4P7O2, 10 m Mn a3VO4 and protease inhibitor cocktail (Complete Mini, Roche, Mannheim, Germany). Protein isolation, quantification and Western Blot analysis followed a previously described protocol26. Quantification was performed by chemiluminescent imaging with a FluorChem HD2 (Alpha Innotech, San Leandro, Calif., USA) using the respective software. Values obtained from densitometry of target proteins were normalized to those of the housekeeping protein β-tubulin for the same samples.

Animals and Housing. Male C57Bl/6N were purchased from Charles River (Sulzfeld, Germany), male IL6 knock-out mice on a C57Bl/6J background (strain 002650) and males IL6 KO and WT mice were decapitated and cortical tissue was dissected on ice, homogenized and SERT containing membranes were prepared in a buffer containing 10 mm Tris-HCl (pH 7.5), 1 mM EDTA, 2 mm MgCl2. Radioligand binding assays were carried out essentially as previously described27. Primer sequences were used: forward 5′GATGAGGAACGAAGAC3′ and reverse 5′TTACACCTGCCCAACACC3′.

Manipulations carried in the absence of the primary antibody (MockIP) were used to define the assay blank. A number of relative levels of STAT3 binding to the SERT promoter were determined by qRT-PCR; the background (i.e., amplicons produced in the absence of a specific immunoprecipitation) was set 1. For the calculation of signal

roventricular (i.c.v.) cannula was verified in each case by coronal sectioning and his-

Animals were single-housed in standard transparent laboratory cages one week prior to the start of behavioral experiments, which were all carried out during the light-phase of the light/dark cycle. Behavioral analyses were carried out by an experimenter blinded to the experimental groups.

Drug treatment. Escitalopram was dissolved in 0.9% NaCl and administered by intraperitoneal (i.p.) injection at a dose of 10 mg/kg in 0.25 mL. Control animals received 0.9% NaCl injections (i.p.). Behavioral testing was carried out 30 min after drug treatment. Stattic was dissolved in DMSO and diluted in 0.9% NaCl and administered by (i.p.) injection at a dose of 5 mg/kg in 0.25 mL. Control animals received equal amount of DMSO diluted in 0.9% NaCl (i.p.). Behavioral testing was carried out 24 hrs after drug treatment.

Forced swim test. The forced swim test (FST) was carried out as previously described during the light phase of the day26. Briefly, mouse behavior was tracked using an infrared video camera and monitored by VIDEOTRACK [PORSOLT] software (Viewpoint®, France). The test chamber consisted of a Plexiglas beaker (diameter: 19 cm, depth: 23 cm), filled with tap water (23–25 °C). The test had a total duration of 6 min of which the last 4 min were used for the analysis of immobility. Percentage of immobility was calculated as the amount of time (in sec) the animal spent immobile during the total evaluation period (240 sec). Immobility is defined as cessation of all movements except the minimum postural adjustments required for maintaining the nostrils above the surface of the water to allow for breathing26.

Sucrose preference test. The SPT test was carried out essentially as described by Khan et al27. Briefly, during a 4 days training phase, mice were habituated to drink a 2% sucrose solution. The day before the sucrose preference test mice were deprived of water and food for 18 hours. During the test, subjects were given a free choice between two bottles, one with the sucrose solution and the other with water. Mice were tested over 3 h, starting at 9:00 a.m. To prevent possible effects of side preference in drinking behavior, the position of the bottles (right/left) was alternated between animals. In the absence of a specific immunoprecipitation) was set 1. For the calculation of signal

Novelty-Suppressed Feeding Test. The novelty-suppressed feeding (NSF) paradigm was performed according to a previous study28 with minor modifications. The testing apparatus consisted of a clear polycarbonate arena (33 × 47 × 17 cm), brightly lit (800 lux). Because our mice were single housed, the control test of 5 min food consumption was carried out in each mouse home cage, placed aside to the NSF arena, in dim light (30 lux).

Brain dissection. Mice were sacrificed by neck dislocation and brains were rapidly dissected on ice. Isolated tissues were stored in RNAlater® (Ambion, Austin, TX, USA) for RNA isolation experiments or immediately immersed in liquid nitrogen and kept at − 80°C for protein isolation.

Central administration of IL-6. Recombinant mouse IL6 was purchased from Invitrogen (MD, USA) and diluted in artificial CSF (124 mM NaCl, 2.5 mM KCl, 2.0 mM MgSO4, 1.25 mM KH2PO4, 26 mM NaHCO3, 10 mM glucose, 4 mM sucrose, 2.5 mM CaCl2) containing 0.1% bovine serum albumin (BSA) as carrier protein. Ten weeks old male C57Bl/6N mice were used for this experiment. At the time of surgery, mice were anesthetized using a mix of ketamine (Ketanest®, Pfizer Corporation Vienna, Austria 20 mg/kg) and xylazine (Rompun®, Bayer Vienna, Austria 20 mg/kg) mix administered i.p. and fitted with a stainless-steel guide cannula (26 gauge; Plastics One, Bilaney, Germany) aimed at the lateral ventricle. Coordinates relative to skull at bregma: anterior–posterior, 0.26 mm; mediolateral, −1.0 mm; dorso-ventral, −2 mm (relative to surface of the skull). Post-surgery analgetic treatments and applied and mice were transferred to individual cages and handled daily for 3 min per day during a seven days recovery period. 3 µl of IL-6 (1 µg total) or CSF solution was manually injected into the lateral ventricle over a 2 min period (rate of infusion at 1.5 µl/min-1). The infusion cannula was maintained in place for an additional 5 min to prevent backflow leakage. Mice were sacrificed 24 hours after injection and hippocampi were collected for Western Blot analysis. The position of the intracerebroventricular (i.v.c.) cannula was verified in each case by coronal sectioning and histological analysis (Nissl staining) at the completion of each experiment.

Data collection and statistical analysis. For statistical analyses of differences between two groups, data were tested for normality by using the Kolmogorov–Smirnov test, followed by unpaired two-tailed Student’s t-tests (results depicted in Figures 1a–1f, 2a–2d, 2f–2g and 3g). For experiments involving more than two groups and/or more than one factor, one-way (results depicted in Figure 3c) or two-way ANOVA analysis of variance (ANOVA) analysis. For experiments depicted in Figures 2a and 30 it was carried out as appropriate. Post-hoc pairwise comparisons, with Bonferroni correction for multiple comparisons, were conducted where indicated. An α level of 0.05 was adopted in all instances. All analyses were carried out using BioStat 2009 professional software (AnalystSoft Inc., Alexandria, VA, USA).
2. Lindqvist, D. et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological psychiatry 66, 287–292, doi:10.1016/j.biopsych.2009.01.030 (2009).

3. Monje, F. J. et al. Constant darkness induces IL-6-dependent depression-like behavior through the NF-kappaB signaling pathway. J Neurosci 31, 9075–9083, doi:10.1523/jneurosci.1537-11.2011 (2011).

4. Sukoff Rizzo, S. J. et al. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Translational psychiatry 2, e199, doi:10.1038/tp.2012.120 (2012).

5. Mann, J. J. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 21, 995–1055, doi:10.1016/s0893-133x(99)00040-8 (1999).

6. Blier, P. & El Mansari, M. Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 368, 20102536, doi:10.1098/rstb.2012.0536 (2013).

7. Samuels, D. J., Jayanthi, L. D., Bhat, N. R. & Ramamoorthy, S. A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J Neurosci 25, 29–41, doi:10.1523/jneurosci.3754-04.2005 (2005).

8. Zhu, C. B., Carneiro, A. M., Dostmann, W. R., Hewlett, W. A. & Blakely, R. D. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. The Journal of biological chemistry 280, 15649–15658, doi:10.1074/jbc.m410185820 (2005).

9. Zhu, C. B., Blakely, R. D. & Hewlett, W. A. The proinflammatory cytokines interleukin-1-beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31, 2121–2131, doi:10.1038/np/pp.2010.129 (2006).

10. Zhu, C. B. et al. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 35, 2510–2520, doi:10.1038/np.2010.116 (2010).

11. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Graeve, L. & Heinrichs, P. p38 MAPK activation and TNF-alpha production in ligation-induced acute pancreatitis. Biochem J 334 (Pt 1), 297–314 (1998).

12. Chourbaji, S. et al. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol Dis 23, 587–594, doi:10.1016/j.nbd.2005.03.001 (2006).

13. Lira, A. et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biological psychiatry 54, 960–971 (2003).

14. Boyarskikh, U. A., Bondar, N. F., Filipenko, M. L. & Kudryavtseva, N. N. Downregulation of serotonergic gene expression in the raphe nuclei of the midbrain under chronic social defeat stress in male mice. Mol Neurobiol 48, 13–21, doi:10.1007/s12035-013-8413-y (2013).

15. Mueller, B. R. & Bale, T. L. Sex-specific programming of offspring emotionality after stress early in pregnancy. J Neurosci 28, 9055–9065, doi:10.1523/jneurosci.1424-08.2008 (2008).

16. Schust, J., Sperl, B., Hollis, A., Mayer, T. U. & Berg, T. Static: a small-molecule inhibitor of STAT3 activation and dimerization. Chemistry & biology 13, 1235–1242, doi:10.1016/j.chembiol.2006.09.018 (2006).

17. Racca, S. et al. Effects of swim stress and alpha-MSH acute pre-treatment on brain 5-HT transporter and corticosterone receptor. Pharmacology, biochemistry, and behavior 81, 894–900, doi:10.1016/j.pbb.2005.06.014 (2006).

18. Tang, M. et al. Immobility responses between mouse strains correlate with distinct hippocampal serotonin transporter protein expression and function. The international journal of neuropsychopharmacology official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 17, 1737–1750, doi:10.1017/s146114571400073x (2014).

19. Samuel, I., Zaheer, S. & Zaheer, A. Bile-pancreatic juice exclusion increases p38MAPK activation and TNF-alpha production in ligation-induced acute pancreatitis in rats. Pancreatology 5, 20–26, doi:10.1159/000344886 (2005).

20. Nunez, J. Primary Culture of Hippocampal Neurons from P0 Newborn Rats. J Vis Exp Exp doi:10.3791/895 (2008).

21. Zeitelhofer, M. et al. High-efficiency transfection of mammalian neurons via nucleofection. Nat Protoc 2, 1692–1704, doi:10.1038/nprot.2007.226 (2007).

22. Sucic, S. et al. The serotonin transporter is an exclusive client of the coat protein complex II (COPII) component SEC24C. The Journal of biological chemistry 286, 16482–16490, doi:10.1074/jbc.M111.230307 (2011).

23. Korkhov, V. M., Holy, M., Freissmuth, M. & Sitte, H. H. The conserved glutamate (Glu136) in transmembrane domain 2 of the serotonin transporter is required for the conformational switch in the transport cycle. The Journal of biological chemistry 281, 13439–13448, doi:10.1074/jbc.M111382200 (2006).

24. Nelson, J. D., Denisenko, O. & Bomsztyk, K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 1, 179–185, doi:10.1038/nprot.2006.27 (2006).

25. Griesauer, I. et al. Circadian abnormalities in a mouse model of high trait anxiety and depression. Annals of medicine 46, 148–154, doi:10.3109/07853980.2013.866440 (2014).

26. Castagne, V., Moser, P. & Porots, R. D. Behavioral Assessment of Antidepressant Activity in Rodents Methods of Behavior Analysis in Neuroscience. (Taylor & Francis Group, LLC, 2009).

27. Khan, D. et al. Long-term effects of maternal immune activation on depression-like behavior in the mouse. Transl Psychiatry 4, e363, doi:10.1038/tp.2013.132 Compartmental abnormalities in a mouse model of high trait anxiety and depression. Exp Brain Res 220, 1–12, doi:10.1007/s00221-012-3032-5 (2012).

28. Mineur, Y. S., Picciotto, M. R. & Sanacora, G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biological psychiatry 61, 250–252, doi:10.1016/j.biopsych.2006.04.037 (2007).

Acknowledgments

This work was supported by the Austrian Science Fund (FWF)-funded grants P22424, P3516-B20 and P3516-B20. The contribution of Ms. Marianne Ronovsky, MSc. to the graphical design of the figures is greatly appreciated.

Author contributions

D.D.P. designed the study and wrote the manuscript. E.K. carried out molecular and biochemical analysis and wrote the manuscript. S.S. and F.J.M. performed cell-culture and uptake assays. W.F.D. assisted in gene expression analyses. G.S. carried out biochemical analysis and wrote the manuscript. S.S. and F.J.M. performed cell-culture and biochemical analysis. M.F. contributed to the study design, analysis and interpretation of data and writing of the manuscript.

Additional information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Kong, E. et al. STAT3 controls IL-6-dependent regulation of serotonin transporter function and depression-like behavior. Sci. Rep. 5, 9009; DOI:10.1038/srep09009 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Corrigendum: STAT3 controls IL6-dependent regulation of serotonin transporter function and depression-like behaviour

Eryan Kong1, Sonja Sucic1, Francisco J. Monje1, Sonali N. Reisinger1, Giorgia Savalli1, Weifei Diao1, Deeba Khan1, Marianne Ronovsky1, Maureen Cabatic1, Florian Koban2, Michael Freissmuth² & Daniela D. Pollak1

Scientific Reports 5:9009; doi: 10.1038/srep09009; published online 11 March 2015; updated on 15 July 2015

Sonali N. Reisinger was omitted from the author list in the original version of this Article. This has been corrected in the PDF and HTML versions of the Article.

The Author Contributions section now reads:

DDP designed the study and wrote the manuscript. EK carried out molecular and biochemical analysis and wrote the manuscript. SS and FJM performed cell-culture and uptake assays. WFD assisted in gene expression analyses. GS carried out stereotactic surgeries and behavioral analysis. SNR, DK and MR performed behavioral experiments. FK carried out radioligand binding assays. MC assisted in biochemical experiments. MF contributed to the study design, analysis and interpretation of data and writing of the manuscript.

1Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna. ²Department of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna.